VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma. | ClinicLens
Clear cell sarcoma (CCS) is an ultra-rare sarcoma with no established standard systemic therapy of proven efficacy. Mesenchymal-epithelial transition factor (MET) overexpression drives CCS progression and serves as a promising therapeutic target. Vebreltinib is a highly selective
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.